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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a chronic 
liver disease that might affect up to one-third of the 
adult population in industrialised countries. NAFLD 
incorporates histologically and clinically different non-
alcoholic entities; fatty liver (NAFL, steatosis hepatis) 
and steatohepatitis (NASH-characterised by hepatocyte 
ballooning and lobular inflammation ± fibrosis) might 
progress to cirrhosis and rarely to hepatocellular cancer. 
NAFL increasingly affects children (paediatric preva-
lence is 4.2%-9.6%). Type 2 diabetes mellitus (T2DM), 
insulin resistance (IR), obesity, metabolic syndrome 
and NAFLD are particularly closely related. Increased 
hepatic lipid storage is an early abnormality in insulin 
resistant women with a history of gestational diabetes 
mellitus. The accumulation of triacylglycerols in hepa-
tocytes is predominantly derived from the plasma non-
esterified fatty acid pool supplied largely by the adipose 
tissue. A few NAFLD susceptibility gene variants are 
associated with progressive liver disease, IR, T2DM and 
a higher risk for hepatocellular carcinoma. Although not 
approved, pharmacological approaches might be con-
sidered in NASH patients.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: In this review article, non-alcoholic fatty liver 
disease (NAFLD) spectrum disease is discussed in 
detail. The epidemiology of NAFLD/nonalcoholic ste-
atohepatitis and the relationship of NAFLD to different 
forms of diabetes mellitus including type 2 diabetes 
mellitus and gestational diabetes mellitus are reviewed. 
Attention is paid to the main biochemical events, to 
dysfunctional adipose tissue and visceral adiposity asso-
ciated with NAFLD and insulin resistance, to mitochon-
drial dysfunction and to the role of the entero-insular 
axis in NAFLD. Genetics and potential pharmacological 
approaches are discussed.
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HISTORY
The work regarding non-alcoholic fatty liver disease 
(NAFLD) was launched only three decades ago, when 
Ludwig et al[1] described an “unnamed” and “poorly 
understood” liver disease they named non-alcoholic 
steatohepatitis (NASH) in 20 patients that histologically 
reminded authors of  alcoholic hepatitis with a potential 
of  progression to cirrhosis. Although 20 patients with 
NAFLD today could likely be recruited within one day 
in a lobby of  a hotel, their observation that NASH is an 
obesity-associated disease largely accompanied by dia-
betes mellitus presenting with hepatomegaly and mild 
abnormalities of  liver tests still accurately describes the 
most common clinical findings. There are a number of  
confounding factors in determining the true prevalence 
and incidence of  NAFLD.
EpIdEmIOlOgY Of NAfld/NASH bASEd 
ON HISTOlOgY
NAFLD incorporates histologically and clinically differ-
ent non-alcoholic entities as fatty liver (NAFL, steatosis 
hepatis) and steatohepatitis (NASH) with or without 
fibrosis that might progress to liver cirrhosis and in a few 
cases to hepatocellular cancer[2,3].
The gold standard methodologies are difficult to 
apply in a general population based study. Histologi-
cal assessment had an exclusive role for decades as the 
only method for grading hepatic steatosis; however this 
method has been recently challenged and not only due 
to the difficulties in everyday use for diagnostic purposes 
in this spectrum of  diseases. Hepatic steatosis is defined 
as intrahepatic fat content above 5.5%[4,5] or when more 
than 5% of  the hepatocytes contain typically macrove-
sicular fat on the histology. Steatosis might be graded 
as-S1, mild (up to 10% of  hepatocytes); S2, moderate 
(10% to 30% of  hepatocytes); S3, severe (more than 30% 
of  hepatocytes)-according to the proportion of  the cells 
with macrovesicular changes in the liver cells containing 
fat.
Under routine clinical circumstances, liver biopsy is 
typically indicated when liver tests (LTs) are repeatedly 
and chronically elevated (e.g., for six months) and are of  
unexplained origin. A few biopsy-based studies report 
the NASH prevalence in the general population. Wil-
liams et al[6] recruited 400 outpatients aged 18 to 70 years 
and performed 134 liver biopsies when the screening ab-
dominal ultrasound suggested hepatic steatosis. Although 
ultrasound pre-screening theoretically might implicate 
a selection bias, the reported prevalence of  NAFLD 
was 46% in this United States cohort. The recalculated 
NAFLD prevalence-taking into account those who re-
fused the biopsy and those with normal liver histology-is 
40% based on the biopsy findings. NASH was diagnosed 
in 12.2% of  the entire United States cohort and 29.9% 
of  the NAFLD patients (Table 1). Differences were 
found according to ethnic origin, with the highest risk for 
NAFLD and NASH presented in patients of  Hispanic 
origin (> Caucasian > African-American) and according 
to the presence of  diabetes mellitus (NAFLD prevalence, 
74%, NASH prevalence, 22.2%); the NAFLD patients 
were more likely to be male (58.9%) and of  older age, to 
have a higher BMI and to present with hypertension.
We might conclude that the prevalence of  NAFLD 
and NASH is highly dependent on the structure of  the 
study population due to the significant differences in 
prevalence among different sub-populations. The dif-
ferences in the prevalence and clinical-pathological pre-
sentation are influenced by gender as follows: the males 
among NAFLD patients are more prone to present with 
elevated LTs, histologically determined NASH, hepatic 
fibrosis and higher overall mortality according to the ma-
jority of  studies[7-9].
The NAFLD spectrum diseases do not differ from 
the demographic trends observed in metabolic diseases 
including type 2 diabetes mellitus that affect increasingly 
younger generations decade by decade[10]. The prevalence 
of  NAFL in Poland and NAFLD in the United States 
was 4.2% and 9.6% based on histopathology at autopsy 
in pediatric populations, respectively[11,12]. Excess body-
weight was found in 55.6% of  the children with NAFL 
in the European study, and the highest rate of  NAFLD 
was observed in obese United States children (38%); the 
latter study found a difference in the NAFLD preva-
lence among different sub-populations (ethnic origin) in 
children[11,12].
EpIdEmIOlOgY Of NAfld bASEd 
ON pROTON mAgNETIC RESONANCE 
SpECTROSCOpY
Grading hepatic steatosis by histological examination po-
tentially holds other biases, including sampling and obser-
vation biases. The amount of  triglyceride accumulation 
in the liver could be assumed to be too low to allow the 
formation of  macrovesicles and might not be assessed 
at histology. Proton magnetic resonance spectroscopy 
(1HMRS) has appropriate sensitivity for the quantification 
of  the intrahepatic lipid content and correlates better 
with the biochemical analysis results of  liver specimens 
even if  such a small lipid accumulation is in question[13,14]. 
Compared to traditional histology, 1HMRS based ste-
atosis (intrahepatocellular lipid content, IHCL) grading 
is based on a much larger mass of  hepatic tissue that is 
investigated without the risks of  liver biopsy (27 g vs 100 
mg), providing additional advantages over the invasive 
method[13,14].
The NAFLD prevalence from the studies using 1HMRS 
based IHCL measurements are indicated in Table 1. 
The prevalence of  fatty liver disease in a population-
based study in the United States using a 1HMRS-based 
measurement for the determination of  the intrahepatic 
triglyceride content (HTGC) was 34%, and in over 90% 
of  the 2287 enrolled individuals, it was because of  non-
alcoholic causes[4]. The results of  this multi-ethnic study 
demonstrated differences in the prevalence of  hepatic 
steatosis among the different ethnic groups studied, with 
a higher prevalence in Hispanic patients, explained by 
the higher prevalence of  obesity and insulin resistance. 
The authors concluded that ethnic differences in the 
prevalence of  hepatic steatosis in the study reflected 
those observed previously for NAFLD-related cirrhosis 
(Hispanics > whites > blacks). The finding that the ma-
jority of  subjects (79%) with NAFLD had normal levels 
of  serum alanine aminotransferase should be taken into 
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account when evaluating population-based studies using 
score systems that incorporate LT in the diagnosis of  
NAFLD[4].
In a recent study, biochemically measured hepatic 
triglyceride levels correlated significantly with the hepatic 
lipid level (IHCL) measured with 1HMRS. The histologic 
and 1HMRS grading of  fatty liver was in agreement in 
the majority (65%) of  these C-virus infected patients. In 
contrast, no linear correlation between the biochemically 
determined liver triglyceride content and histological ex-
amination was found[15].
UlTRASOUNd bASEd NAfld 
pREVAlENCE
The diagnostic plethora of  NAFLD is further compli-
cated by many studies using ultrasonography data to 
identify patients with NAFLD, although ultrasonography 
might not be regarded as accurate radiologic modality 
as the 1HMRS in measuring the intrahepatic lipid level. 
The third National Health and Nutrition Examination 
Survey (NAHNES) assessed the prevalence of  NAFLD 
from 1988 to 1994 in the United States based on the 
ultrasonography data of  12454 adults. They estimated 
that 28.8 million adults might be diagnosed with NAFLD 
in the United States; the corresponding prevalence is 
19%[16]. The data obtained from the NAHNES study 
confirmed that NAFLD occurs with a higher prevalence 
in Mexican-Americans compared to non-Hispanic whites 
and non-Hispanic blacks. NAFLD was independently as-
sociated with insulin resistance and diabetes; and, among 
people without diabetes, with dyslipidaemia and obesity. 
The study confirmed that NAFLD is more common in 
males[16]. The NAFLD prevalence in the Italian Dionysos 
project in adults with and without suspected liver dis-
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Table 1  Prevalence of non-alcoholic fatty liver disease, non-alcoholic fatty liver and non-alcoholic steatohepatitis
NAFLD/NAFL prevalence NASH prevalence Population studied Population size Method of diagnosis Remark Ref.
46 (40)% NAFLD in the entire US 
cohort
12.2% in the US 
entire cohort
18-70 yr aged US 
cohort 
328 Liver biopsy (in 
134 ultrasound pre-
screend patients)
[6]
29.9% in patients 
with NAFLD
Greatest risk for both 
NAFLD and NASH 
in Hispanics and with 
diabetes
NAFL: 49.3%-mild, moderate, and 
severe
NAFL in 38.9%, 9.0% and 1.4% donor 
candidates respectively (mild steatosis 
was defined as fatty changes in 5%-30% 
of hepatocytes, moderate steatosis in 
30% to 60% of hepatocytes, and severe 
steatosis in > 60% of hepatocytes 
without significant inflammation on 
liver histology)
2.2% (Asian 
population)
Korean living liver 
donor candidates 
589 589 US guided liver 
biopsy
[126]
NAFL: 4.2% in pediatric European 
population 
1% (pediatric 
population) 
European children 
(6 mo-18 yr old)
342 
medicolegal 
autopsy 
reports/265 
children died 
from trauma
Histopathology 
at autopsy (and 
typical macroscopic 
imaging)
Excess body weight was 
observed in 55.6% of 
children with NAFL
[11]
NAFLD 9.6% in pediatric US 
population fatty liver was defined as 
> or = 5% of hepatocytes containing 
macrovesicular fat
NR United States 
children (2-19 yr 
old) 
742 children 
(2-19 yr old) 
who had 
autopsy (form 
1993 to 2003)
Histopathology at 
autopsy
Different prevalence 
according to 
subpopulation (Asians: 
10.2%; Black: 1.5%; 
Hispanic: 11.8%; White: 
8.6%). The highest rate of 
NAFLD was seen in obese 
children (38%)
[12]
NAFLD 31% in adult Urban US 
population
NR Large, ethnically 
diverse, 
probability-based 
adult population
sample from 
Dallas, Texas, 
United States 
-participants in the 
Dallas Heart Study 
2349 1H-MRS of the liver 
to quantify HTGC
79% of patients with 
hepatic steatosis had 
normal levels of serum 
alanine aminotransferase. 
Different prevalence 
of hepatic steatosis in 
different sub-populations: 
45% in Hispanics, 33% in 
Whites and 24% in Blacks
[4]
Based on histological examination or proton magnetic resonance spectroscopy (1H-MRS) measurement in Hallmark Studies. HTGC: Hepatic triglyceride 
content; NAFLD: Non-alcoholic fatty liver disease; NAFL: Non-alcoholic fatty liver; NASH: Non-alcoholic steatohepatitis; NR: Not reported.
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tance and pancreatic β-cell dysfunction.
The prevalence of  ultrasonographic NAFLD was 
69.4% in 180 patients with T2DM[30]. NAFLD was asso-
ciated with obesity (abdominal), hypertriglyceridemia and 
high-normal ALT levels. The authors concluded that the 
progression of  NAFLD is independent of  the diabetes 
progression[30].
The ultrasonography results of  204 patients with 
T2DM showed fatty infiltration in 62.2% of  the patients; 
NAFLD was confirmed by liver biopsy with subsequent 
histology in 87% of  the patients, indicating a 54.11% 
histologically confirmed prevalence in T2DM. Steato-
hepatitis and fibrosis were found in 38.9% and 23.2%, 
respectively, of  Indian patients with T2DM[31].
Leite et al[32] found a 78% NASH prevalence at the 
histological examination in nearly 100 patients with 
T2DM and US evidence of  NAFLD. The presence of  
high triglyceride, low HDL-cholesterol and increased 
ALT levels were independently associated with a higher 
risk of  histologically confirmed NASH. The prevalence 
of  advanced fibrosis (≥ stage 2) was found in 38% and 
55% of  the patients depending on the pathologist who 
conducted the histological examination. The presence 
of  NASH was independently correlated with high serum 
γGT levels, older age and male gender[32].
Gestational diabetes mellitus
Recent novel findings have emerged to confirm the rela-
tionship between diabetes mellitus and NAFLD: Women 
with a history of  gestational diabetes mellitus (GDM) 
have an increased risk of  developing T2DM decades 
later. Prikoszovich et al[33] recruited women with a history 
of  GDM (pGDM) four to five years after delivery and 
assessed the glucose tolerance and oral glucose insulin 
sensitivity to measure the whole-body insulin sensitivity 
during a 75 g CH OGTT. The lipid storage in the muscle, 
liver and flux through the ATP synthase were measured 
using 1H/31P magnetic resonance spectroscopy. In a com-
parison with women without any risk factor for T2DM, 
the hepatic content of  lipids (HCL) was doubled in the 
insulin resistant pGDM women, despite they had normal 
glucose tolerance. HCL correlated positively with the 
body fat mass and inversely with insulin sensitivity. The 
authors concluded that increased hepatic lipid storage is 
an early and predominant abnormality in insulin resistant 
women with a history of  GDM.
The fatty liver index (FLI) -measured using 1HMRS- 
in women with previous GDM predicted further meta-
bolic deterioration and subjects with the highest FLI 
values showed significant alterations in FFA kinetics with 
a higher risk to develop T2DM in the future[34]. The re-
sults of  these studies should be taken into consideration 
when the role of  NAFLD in determining the hepatic and 
whole body insulin sensitivity is under scrutiny in glucose 
tolerant individuals with insulin resistance.
In 2013, Brumbaugh et al[35] assessed the intrahepatic 
lipids in the neonatal offspring of  obese women with 
gestational diabetes. The neonates born to obese women 
ease was 25% and 20%, respectively using the US based 
method for identification[17]. The prevalence of  NAFLD 
in Japan increased to 2.4-fold from the 12.6% preva-
lence found in 1989 to the 30.3% prevalence observed 
in 1998[18]. A lower prevalence was reported in India, us-
ing ultrasonography for the identification of  NAFLD: 
the prevalence of  NAFLD was 18.9% in adults above 
20 years of  age, with a higher prevalence of  NAFLD in 
males than females (24.6% vs 13.6%)[19].
A number of  studies report the aminotransferase-
based approach to diagnose; due to the observation that 
more than 75% of  the patients with steatosis might have 
normal LT values, these studies are not discussed in detail 
here[4].
ASSESSmENT Of fIbROSIS ANd 
STEATOHEpATITIS
In most patients with NAFLD, a non-invasive score pro-
posed by Angulo et al[20] could be applied to assess liver fi-
brosis because advanced fibrosis could be diagnosed with 
accuracy in 90% of  the cases. The authors analysed the 
clinical and liver biopsy data of  more than 700 patients to 
construct this simple scoring system. Transient elastog-
raphy (Fibroscan), which is a radiological modality used 
with high accuracy to non-invasively assess the degree of  
fibrosis based on the measurement of  liver stiffness[21,22], 
might detect even low-grade steatosis because of  a re-
cently described novel ultrasonic controlled attenuation 
parameter of  the machine[23].
Although there are promising biomarkers such as 
cytokeratin-18 fragments for NASH to be potentially ap-
plied as diagnostic tools in the future[24], the accurate di-
agnosis of  NASH in some cases might require a liver bi-
opsy. A biopsy is typically indicated in the cases in which 
the liver tests (LTs) are repeatedly elevated in a chronic 
manner (e.g., for six months) and are of  unexplained ori-
gin and when the patient must be carefully investigated 
for alternative diagnoses (e.g., to measure assess hepatic 
iron concentration in a C282Y HFE heterozygote indi-
vidual; when the case is suggestive of  autoimmune liver 
disease; rarely, when the diagnosis of  Wilson disease may 
not be established without quantitation of  the liver cop-
per content; in other storage diseases; or in rare distinct 
forms of  liver disease)[25-29].
WHY IS NAfld WORRISOmE?
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) and NAFLD are par-
ticularly closely related. This relationship among T2DM, 
insulin resistance (IR) and NAFLD is expected because 
insulin is subsequently delivered directly to the portal vein 
after secretion, taking the same route as the absorbed 
glucose, and the liver eliminates a large portion of  portal 
insulin at the first pass.
Obesity in NAFLD is associated with dysfunctional 
adipose tissue, and lipotoxicity promotes insulin resis-
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with GDM underwent MRS for intrahepatic lipid content 
determination at 1-3 wk of  age and demonstrated a mean 
68% increase in the IHCL compared with infants born to 
normal-weight mothers. The intrahepatic fat deposition 
in the neonates positively correlated with the maternal 
pre-pregnancy BMI and not with subcutaneous adiposity.
"Metabolic syndrome"
Although many authors agree that the “metabolic syn-
drome” is a cluster of  risk factors, but whether it may 
correctly be considered a syndrome is strongly ques-
tioned[36]. Provided the term “metabolic syndrome” is 
accepted, insulin resistance should be at the core of  the 
“syndrome”, and many authors agree that NAFLD that 
is generally asymptomatic is frequently associated with 
obesity, type 2 diabetes and the “metabolic syndrome”[17]. 
Although a statement was published for synchronising 
the various definitions for metabolic syndrome[37], our 
experience confirmed that a large proportion of  patients 
with NAFLD did not fulfill the “metabolic syndrome” 
criteria (49%-46% depending on the NCEP in ATP-Ⅲ[38] 
or the AHA and IDF joint criteria[37] were applied). The 
high proportion of  NAFLD patients without “metabolic 
syndrome” was observed despite that the HOMA2-IR 
values of  the NAFLD patients were even higher in this 
study population than those with T2DM, provided that 
the NAFLD patients were excluded from the latter study 
group. None of  the definitions of  “metabolic syndrome” 
could be appraised as a consensus due to that the signifi-
cant proportion of  insulin-resistant NAFLD patients are 
excluded by these criteria[39].
bIOCHEmISTRY
The major biochemical event in NAFLD is the accu-
mulation of  triacylglycerols (TAG) in the hepatocytes. 
Because of  the strong associations described above and 
to understand the relation of  NAFLD to whole-body 
metabolic status, Donnelly et al[40] conducted a study using 
gas chromatography/mass spectrometry. Hepatic TAG 
might accumulate from different sources in the hepato-
cytes as follows: TAG as a nutrient after absorption from 
the intestine are delivered via chylomicrons to the liver, 
where they might subsequently be secreted as lipopro-
teins. Hepatic TAG synthesis is possible, and this process 
requires fatty acids and glycerol in the liver The required 
fatty acids might be from the plasma non-esterified fatty 
acid pool (NEFA), and they might be produced in the 
liver as de novo hepatic lipogenesis. It has been reported 
that approximately 60% of  the TAG accumulated in the 
liver is derived from the plasma NEFA pool, even in the 
fed state, and that adipose tissue is the largest contributor 
to the fatty acid content of  the plasma NEFA pool (80% 
in the fasted state). One-quarter of  the TAG accumula-
tion is derived from hepatic de novo lipogenesis that is 
elevated in the fasting state and demonstrates no diurnal 
variation, whereas approximately 15% is derived from the 
dietary intake. The situation is even worse when insulin 
resistance - a hallmark of  metabolic syndrome - is also 
present because of  the lack of  (insulin induced) down-
regulation of  the hormone sensitive lipase that eventually 
results in enhanced lipolysis and an increased efflux of  
free fatty acids to the plasma NEFA pool from the adi-
pocytes. Hyperglycaemia (and hyperinsulinaemia) induces 
SREBP-1c and ChREBP in the liver, and these transcrip-
tion factors subsequently activate genes that are required 
for lipogenesis, eventually resulting in increased hepatic de 
novo lipogenesis. Hepatic de novo lipogenesis is increased in 
insulin-resistant states and in NAFLD[41]. Beta-oxidation 
of  fatty acids is increased in patients with NASH; the ox-
idation might not overcome the increased hepatic TAG 
production, and the increased NEFA oxidation might 
result in increased oxidative stress, enhancing the transi-
tion of  NAFL to NASH[42,43]. This (patho)biochemical 
path provides the reason that the association is remark-
ably strong between fatty liver and obesity-related insulin 
resistance[40,44].
NAfld CONCURRENTlY WITH VISCERAl 
ANd SUbCUTANEOUS AdIpOSITY ANd 
INSUlIN RESISTANCE
Is there accurate morphological evidence to support this 
biochemistry-driven hypothesis that the intrahepatic lipid 
content is hand-in-hand with different adipose tissue 
deposits, particularly the visceral adipose tissue accumula-
tion that is strongly associated in impaired glucose me-
tabolism?
Bosy-Westphal et al[45] assessed the fat volume includ-
ing the visceral fat volumes (VAT), the pericardial adipose 
tissue (PAT, a well-known marker of  visceral adiposity) 
and the abdominal subcutaneous adipose tissue using 
MRI and compared the results to the IHCL quantified by 
the highly sensitive 1H-MRS method in thirty overweight, 
not yet diabetic women. The participating individuals 
were restricted to a low calorie diet for three months; 
at baseline, the visceral adipose tissue volume and PAT 
correlated with the IHCL as well as with the insulin resis-
tance measured with the euglycaemic hyperinsulinaemic 
clamp and the homeostatic model assessment (HOMA)-
IR. The strength of  the relationship between the visceral 
fat volume and IHCL is shown by the finding that the 
reductions in IHCL induced by the dietary intervention 
and loss of  body weight were only correlated with the 
decrease in VAT. The exceptional role of  NAFLD in 
determining insulin resistance is confirmed by the im-
provements in HOMA-IR and HOMA2-%B after three 
months of  diet and weight loss that were only related to 
the decrease in IHCL[45].
The interpretation of  HOMA-IR has been recently 
challenged. Traditionally, HOMA-IR reflects the degree 
of  insulin resistance; however, these estimates based on 
the fasting plasma insulin and glucose concentrations[46] 
do not take into account whether the secretion of  insulin 
by the pancreatic β cells is altered or if  an alteration is 
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in the insulin removal (clearance). The differentiation of  
total body insulin resistance, peripheral insulin resistance 
and hepatic insulin resistance merits research attention. A 
recent novel interpretation of  HOMA-IR suggests that 
it is not a precise estimate of  peripheral insulin action 
rather it might reflect the ability of  insulin to suppress 
hepatic glucose production in the fasting state[47]. The 
clamp technique used in the previously mentioned study 
measures the peripheral insulin action in non-diabetic 
individuals resulting from hyperinsulinaemia during the 
measurement that is high enough to inhibit the hepatic 
glucose production completely[48]. This concept should 
be validated in studies using an insulin concentration that 
is lower than that regularly used during an euglycaemic-
hyperinsulinaemic clamp measurement to avoid the abso-
lute inhibition of  hepatic glucose production[47]. Provided 
that this hypothesis regarding HOMA-IR is accurate, 
the 1H-MRS based follow-up observation that improve-
ments in HOMA-IR and HOMA2-%B after dietary in-
tervention were only related to the decrease in the IHCL 
indicates that a decrease in the intrahepatocellular lipid 
content increases the ability of  insulin to suppress the 
hepatic glucose production in the fasting state, which is a 
major determinant of  fasting plasma glucose levels[45].
In addition the contribution of  the subcutaneous 
adipose tissue (SAT) to the whole-body adipose tissue 
dysfunction has been also recently confronted against the 
broadly accepted “innocent bystander to VAT” concept. 
The results of  an in vivo human study that functionally as-
sessed SAT in patients with histology-confirmed NASH 
provided evidence that the abdominal SAT in NASH pa-
tients is highly insulin resistant and required > 6 × more 
insulin to the gain similar degree of  glycerol release sup-
pression (referring to impaired suppression of  lipolysis in 
SAT by insulin) than in healthy subjects. Authors there-
fore suggested that abdominal SAT is dysfunctional in 
NASH and plays a profound role in NASH development 
and lipotoxicity[49].
lIpOTOXICITY
Free fatty acids (FFA) are directly hepatotoxic, and FFA 
levels are elevated in patients with NASH and correlate 
with disease severity[50]. Patients with severe fibrosis 
shown by liver biopsy had significantly greater serum 
concentration of  free fatty acids than did the patients 
without severe fibrosis[50]. Saturated FFAs (e.g., palmitate) 
are apparently more hepatotoxic than unsaturated (mono-
unsaturated) FFAs (e.g., palmitoleate); palmitoleate (known 
as a lipokine) was demonstrated to suppress hepatic 
steatosis[51,52]. Unsaturated fatty acids do not induce endo-
plasmic reticulum (ER) stress or apoptosis and are able to 
rescue the palmitate-induced ER stress and apoptosis in 
liver cells. It has been proposed that the difference in tox-
icity between saturated and unsaturated fatty acids is that 
unsaturated FFAs are more easily esterified into neutral 
triglycerides[53,54].
The impairment of  liver cellular capacity in FFA utili-
sation, incorporation to TAGs and export contributes to 
the development of  NASH, and hepatic injury is further 
accentuated by pathological FA oxidation and altered cell 
membrane composition[55]. Lipotoxicity induces hepatocel-
lular apoptosis; Kupffer cell activation; impaired insulin 
signaling and hepatic insulin resistance; and hepatic stellate 
(Ito) cell activation with subsequent fibrosis. These patho-
logical processes might eventually lead to cirrhosis[55].
dIACYlglYCEROl ACYlTRANSfERASE 
2: dISSOCIATION Of STEATOSIS ANd 
INflAmmATION-fIbROSIS
The hepatotoxicity of  saturated FFAs is further sup-
ported by the genetic deletion of  diacylglycerol acyltrans-
ferase 2 (DGAT2) in mice models as follows: in parallel 
with the decreased TAG synthesis due to the the in-
creased oxidative stress from the lack of  intracellular FFA 
esterification, hepatocellular apoptosis with subsequent 
fibrosis occurs, resulting in the dissociation of  hepatic 
steatosis and hepatic fibrosis in the NASH model[56,57]. 
Overexpression of  DGAT2 in the experimental model 
causes hepatic steatosis without concomitant liver fibrosis 
or insulin resistance, providing evidence for the different 
roles that toxic saturated FFAs and TAGs have in the de-
velopment of  NAFLD[57,58].
The pathological effect of  lipotoxicity is not limited 
to the liver cells, and it might affect the pancreatic β-cells, 
contributing to the β-cell dysfunction that is frequently 
observed in T2DM[59]. This pathology that affects both 
the liver and the pancreatic β-cells is highly important in 
determining the plasma glucose levels.
Lipotoxicity in the pancreatic β -cells
The intracellular signaling pathways altered because of  
lipotoxicity should partially overlap in the liver cells and 
in the pancreatic β-cells (Figure 1).
Saturated fatty acids, among other factors, induce 
endoplasmic reticulum stress that induce JNK activation 
via the IRE1α/ASK1, a signal that has been described in 
pancreatic β-cells as well as in liver cells[60,61]. Subsequent-
ly, the activation of  the JNK pathway induces the “sen-
sitiser” BH3 proteins (DP5, Bad, Bik), which bind to the 
anti-apoptotic Bcl-2 proteins such as Bcl-2 and Bcl-XL; 
these proteins designate the pro-apoptotic BH3-only pro-
teins, BIM and PUMA (“activators”), eventually leading 
to their activation, which results in the apoptotic death 
of  the pancreatic β and liver cells via Bak and Bax[61-63]. 
There is a substantial homology of  this unsaturated FFA 
induced path and the path of  cytokine induced β cell 
apoptosis. Palmitoleate (a mono-unsaturated fatty acid) 
could inhibit lipoapoptosis by blocking the endoplasmic 
reticulum stress-associated increases of  the BH3-only 
proteins, Bim and PUMA, in hepatocytes[64]. The deterio-
rating β cell function, in combination with the increasing 
hepatic IR and the decreasing suppression of  hepatic 
glucose output, leads to hyperglycaemia that eventually 
9077 July 21, 2014|Volume 20|Issue 27|WJG|www.wjgnet.com
Firneisz G. NAFLD and T2DM: The liver disease of our age?
might directly (glucotoxicity) and by biochemical and 
metabolic consequences further promote this pathologic 
process. This cross-talk between the metabolic and cyto-
kine induced pathways might facilitate the identification 
of  novel drug targets (e.g., DP5, Bim) that would inhibit 
the unsaturated FFA induced ER stress mediated apop-
totic liver cell death and possess protective properties 
against cytokine induced pancreatic β cell death[60-63]. The 
cytokines, growth factors and inflammatory mediators 
that are important in NAFLD are summarised in Table 2.
mITOCHONdRIAl dYSfUNCTION
A defective hepatic mitochondrial respiratory chain 
(MRC) was described in NASH[65]. The mitochondrial 
dysfunction, as measured by the activity of  the MRC 
complexes in liver tissue, was correlated with the serum 
TNF-alpha levels and with the degree of  insulin resis-
tance that were higher in NASH and with the BMI[65]. In 
addition to the mitochondrial dysfunction, Sanyal et al[66] 
described structural mitochondrial defects including the 
loss of  the mitochondrial cristae and paracrystalline in-
clusions, the presence of  linear crystalline inclusions and 
mitochondrial swelling in patients with NASH. Patients 
with T2DM of  long duration might have decreased ATP 
production after fasting and after fructose administration. 
The mitochondrial dysfunction in NAFLD, from lipo-
toxicity, oxidative stress and as a result of  inflammatory 
mediator effect, alters the hepatic energy metabolism, as 
recently reported by Koliaki and Roden[67].
ENTERO-INSUlAR AXIS (dpp-4 ANd 
INCRETINS) IN NAfld
A number of  studies have assessed both the glucagon-
like peptide-1 (GLP-1) and glucose dependent insuli-
notropic peptide induced insulin secretion in T2DM 
patients and concluded that the response to the incretin 
hormone stimuli might be compromised as an early 
phenomenon in T2DM[68-71]. In the carriers of  the tran-
scription factor 7-like 2 gene polymorphism (TCF7L2-
rs7903146, a widely known risk polymorphism in T2DM 
development) the GLP-1 induced insulin secretion, and 
not the GLP-1 secretion, is impaired[72]. Similar find-
ings were presented for a common genetic variant in the 
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Figure 1  Endoplasmatic reticulum stress caused by saturated free fatty acids. Endoplasmatic reticulum stress caused by saturated free fatty acids, via three 
main mediators [inositol-requiring endoplasmic reticulum-to-nucleus signal kinase 1α (IRE1α), activating transcription factor 6 (ATF6) and RNA-dependent protein 
kinase (PRK)-like endoplasmic roticulum (ER) kinase (PERK)], results in the activation of c-Jun N-terminal kinase (JNK) and C/ CCAAT/enhancer binding protein (EBP) 
homologous protein. The sequence of BH3 protein activation based on a sensitizer and an activator group was described by Gurzov and Eizirik in β-cells[62,63]. The 
sensitizers bind the anti-apoptotic proteins Bcl-2, Bcl-XL and Mcl-1 and release the activators from this bond. JNK both mediates the induction of the sensitizer and 
the activator BH3 proteins and also activates Bax. Upregulation of Bcl-2 interacting mediator of cell death (BIM) and p53 upregulated modulator of apoptosis (PUMA) 
was also demonstrated in liver cells as a ruslt of free fatty acid (FFA) induction. Proinflammatory cytokines also activate JNK. ER sterss also results in CHOP actvation 
and subsequently the activation of the activator BH3 proteins. This complex signaling pathway might link the metabolic (saturated FFAs) stress and the effect of pro-
inflammatory cytokines both in the pancreatic β-cell as well as in liver cells.
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WFS1 gene, and carriers of  the polymorphism had im-
paired GLP-1-induced insulin secretion independently of  
insulin sensitivity[73]. Variants of  the KCNQ1 (rs151290, 
rs2237892 and rs2237895) gene altered the endogenous 
GLP-1 secretion[74,75].
Despite these well-designed, elegant studies that as-
sessed the role of  the entero-insular axis in T2DM and its 
association with the risk gene polymorphisms in T2DM, 
there is limited data regarding the role of  the entero-in-
sular axis in NAFLD. Recently, β cell connectedness has 
been reported to influence the incretin-induced insulin 
secretion in human islets, and lipotoxicity was demon-
strated to be able to disrupt this incretin-regulated human 
β cell connectivity that might result in the loss of  the co-
ordinated islet response to metabolic stimuli[76].
Increased serum DPP-4 activity (the soluble form 
of  the enzyme in human sera) was described in patients 
with NAFLD in comparison to healthy controls and 
T2DM patients, provided that T2DM patients who pre-
sented with clinically obvious (with an US and biochemi-
cal based diagnosis) NAFLD were excluded from the 
study group[39]. We found a positive correlation among 
the γGT, ALAT and serum DPP-4 activities in NAFLD 
that supports the finding that the excess DPP-4 found in 
the serum of  NAFLD patients is of  hepatic origin. We 
concluded that it is the presence of  (fatty) liver disease 
that primarily influenced the serum DPP-4 enzymatic 
activity and not hyperglycaemia alone[39]. Subsequently, 
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Table 2  Adipokine hormones, cytokines, growth factors and other mediators that play important role in non-alcoholic fatty liver 
disease pathology
Mediator/pathway Observation /proposed mechanism Ref.
Adiponectin Shown to have anti-inflammatory and antifibrotic activity, serum levels were found to be decreased in 
NAFLD and NASH patients. Plasma adiponectin in NAFLD is related to hepatic insulin resistance and 
hepatic lipid content - not to liver disease severity
[127]
Ghrelin Serum levels were found to be diminished in NAFLD and NASH patients - no correlation with histological 
grade. Ghrelin administration attenuated oxidative stress, inflammation and apoptosis in high fat diet 
induced NAFLD animal model
[128,129]
Leptin Leptin levels are generally known to be higher in the sera of NASH patients, except for a subgroup; serum 
levels were shown to negatively correlate with AST/ALT levels. The livers of leptin-deficient mice were 
found to be unusually sensitive to LPS-induced injury. Recombinant leptin therapy was in clinical trial in 
patients with NASH and low leptin levels - no results were posted
[128] and 
ClinicalTrials.
gov Identifier: 
NCT00596934 
Resistin Serum levels were shown to be significantly higher in patients with NAFLD and NASH [130]
Small bowel bacterial 
overgrowth (SIBO)
Increased gut permeability and tight junction alterations in NAFLD. Higher prevalence of small intestinal 
bacterial overgrowth in NAFLD patients - correlated with the severity of liver steatosis
[131]
Toll-like receptor-4 
(TLR4)
Both the TLR4 (endotoxin-receptor) protein and RNA levels were found to be elevated in liver in NASH [132]
Nuclear factor-κB 
(NF-κB)
Increased activation of NF-κB was found in NASH [132]
Tumor necrosis factor-α 
(TNF-α)
Key mediator of inflammation, serum levels are elevated in NASH. TNF-α expression in adipose tissue is 
upregulated in several models of obesity. In patients, TNF-α levels were shown to be higher in obese than 
in lean individuals, and were correlated with insulin resistance
[133]
Interleukin-6 (IL-6) Increased plasma levels and hepatic expression was described in NASH patients. Increased hepatic IL-6 
production may play an important role in NASH, insulin resistance and diabetes development
[134]
Transforming growth 
factor-β (TGF-β)
A key growth factor and a major inductor of hepatic stellate cell activation and therefore hepatic fibrosis, 
TGF-β signaling in hepatocytes may contribute to hepatocyte death and lipid accumulation via Smad 
signaling and ROS production
[135]
Th17 cells and IL-17 In the livers of mice on a high fat diet and also NASH patients an increased number of hepatic Th17 cells 
could be detected. In mice Il-17 neutralization ameliorated LPS induced liver injury
[136]
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Notch-mTOR pathway Liver-specific ablation of Notch signaling, or its acute inhibition with a decoy Notch1 receptor, prevents 
hepatosteatosis by blocking mTor complex 1 (mTorc1) activity. Notch gain of function induces NAFL 
through constitutive activation of mTorc1
[137]
Mastocyte chymase This enzyme is important in the convertion of angiotenzin-Ⅰ to angiotenzin-Ⅱ and the activation of 
matrix metalloproteinase-9, which both are involved in the development of liver fibrosis. Chymase 
inhibitor prevents the nonalcoholic steatohepatitis in a hamster model
[138]
Galectin 3 Galectin 3 is a β-galactoside-binding lectin with a multiple functions. It is also a receptor of advanced 
lipoxidation endproducts and plays important role in inflammation, fibrosis and carcinogenesis. Its role 
is suspected in NASH. Regression of fibrosis by galectin inhibitors in thioacetamide-induced liver disease 
animal model. Phase 1 Study with a Galectin inhibitor GR-MD-02 in patients with NASH and advanced 
fibrosis
[139,140], 
ClinicalTrials.
gov Identifier: 
NCT01899859
Fibroblast geowth factor 
-19 (FGF19)
Both the intestinal FGF19 production and the hepatic response is impaired in NAFLD patients. A decrease 
in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese 
adolescents
[141]
A few of these molecules are therapeutic targets (e.g., galectin 3) in early phase clinical trials. NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alco-
holic steatohepatitis; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.
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higher hepatic expression of  DPP-4 at the mRNA level 
was described in NAFLD patients, and high glucose 
concentrations increased the DPP-4 expression in the 
HepG2 cells, in contrast to the insulin and FFAs that 
did not alter the DPP-4 expression[77]. The correlation 
among the serum levels of  soluble CD26/DPP-4 activ-
ity and other liver disease biomarkers was also confirmed 
in Asian patients[78-80]. A positive correlation between the 
serum DPP-4 activity and insulin resistance (HOMA2-
IR) in NAFLD was also found that is not surprising 
provided that the serum DPP-4 activity is considered as 
a novel liver disease biomarker. The existence of  such a 
correlation further supported the recent suggestion that 
the soluble form of  DPP-4 is a novel adipokine hormone 
that could induce insulin resistance without the presence 
of  incretin hormones in an experimental system[81]. In a 
meta-analysis, Fadini et al[82] found that the DPP-4 activ-
ity was increased in T2D and was not lowered by glyce-
mic control; the study confirmed that hyperglycaemia 
was not a direct determinant of  DPP-4 activity and was 
lower in metformin-treated patients. A significant role of  
DPP-4 in hepatic glucose metabolism is supported by the 
study of  Edgerton et al[83], who demonstrated that dur-
ing DPP-4 inhibitor therapy (vildagliptin) and GLP-1 co-
treatment, the net hepatic glucose uptake was three-fold 
greater in the DPP-4 inhibitor treated group than in the 
control group that was treated with portal vein GLP-1 
infusion and not with the DPP-4 inhibitor; this effect was 
greater than that predicted by the change in insulin. This 
finding indicates that the DPP-4 inhibitor was able to in-
crease the hepatic glucose disposal beyond the effects of  
GLP-1 on insulin and glucagon secretion.
The effect of  DPP-4 inhibitor therapy on liver fibro-
sis should be assessed, particularly because the fibroblast 
activation protein (FAP), which is a duplicate molecule 
of  DPP-4 (FAP-DPP-4 shows 88% homology at the 
cDNA level), is present at the tissue remodelling interface 
on hepatic stellate cells (HSCs, ITO cells) that primarily 
produce the accumulating extracellular matrix proteins 
(including collagens) in chronic liver diseases, eventually 
leading to fibrosis and cirrhosis of  the liver[84].
dpp-4 INHIbITORS ANd glp-1 mImETICS 
IN NAfld TREATmENT
DPP-4 inhibitors were reported to improve hepatic ste-
atosis and adipose tissue inflammation in mice[85,86]. Hu-
man treatments are also documented, in which the DPP-4 
inhibitor, sitagliptin, was able to provide benefit for a 
refractory case of  NAFLD[87]. Sitagliptin improved hepa-
tocyte ballooning in a diabetic patient with NASH[88]. The 
available data on the use of  GLP-1 mimetics is limited; 
the following effects were reported in animal models: 
improvement of  the FA beta-oxidation; a decrease in the 
liver disease biomarker ALAT and hepatic TAGs; reduced 
ER-stress related hepatocyte cell death; and enhanced 
beneficial macroautophagy[89-92]. The GLP-1 derived non-
peptide (by the cleavage of  the neutral endopeptidase), 
GLP-1 (28-36) amide, was shown to improve glucose 
disposal and decrease hepatic steatosis in high fat diet 
mice. The GLP-1 (28-36) amide suppressed the hepatic 
gluconeogenesis and improved the pyruvate tolerance 
in this model[93]. The large randomised controlled trials 
(RCTs) that would also assess safety issues of  the DPP-4 
inhibitors and the GLP-1 mimetics are missing in NAFL 
patients, as well as in NASH patients, in whom the indica-
tion for (an auxiliary) drug treatment (in addition to diet, 
weight loss and exercise) might be more obvious.
OTHER THERApIES
There is consensus that the most effective treatment of  
NAFL in the overwhelming majority of  cases is lifestyle 
change, including a supervised diet, exercise and weight 
loss. However doctors are not always successful in having 
patients reach this goal, and the potential pharmacologi-
cal approaches that should be considered, predominantly 
in NASH patients, are briefly reviewed.
Metformin
Metformin is experiencing a booming renaissance in the 
treatment of  T2DM; however, this drug has no signifi-
cant effect on liver histology, probably in part because of  
the limited anti-steatogenic effect and failure to increase 
the adiponectin levels[94]. The guidelines do not recom-
mend this biguanide specifically for the treatment of  
NASH (AASLD: Strength 1/Evidence: A)[26,95].
Thiazolidinediones
In contrast to metformin, thiazolidinediones (TZDs) are 
experiencing difficulty as pharmacological agents in hu-
man medicine. In certain countries there are no remaining 
agents from this drug class (e.g., the French Agency for 
the Safety of  Health Products requested a pharmaceutical 
company to suspend the use of  pioglitazone containing 
products for the treatment of  type 2 diabetes in France in 
2011 because of  an increased risk of  urinary bladder can-
cer). EASL and AASLD discussed pioglitazone, outlin-
ing that, from the hepatologist point of  view, glitazones 
consistently provided benefit for patients with NASH 
and could be used to treat biopsy proven steatohepatitis 
(AASLD: Strength: 1, Evidence: B)[26,95]. The associations 
emphasise that the long-term safety of  pioglitazone in 
NASH is not established, and it is likely that no doctor is 
treating NASH isolated from other safety issues[26].
Vitamin E
The nature of  the dilemma with vitamin E is somewhat 
similar to that with the TZDs. A meta-analyses (of  over 
100000 participants) reported increased all-cause mor-
tality with a dose of  vitamin E ≥ 400 IU/d, and one 
meta-analysis found a statistically significant relationship 
between vitamin E dosage and all-cause mortality in a 
dose-response analysis[96,97]. Although others have ques-
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tioned the results obtained from these meta-analyses[98,99], 
recently vitamin E (400 IU/d) was shown to signifi-
cantly increase the risk of  prostate cancer among healthy 
men[100]. According to the AASLD recommendation, 
this vitamin E dose should be doubled (800 IU/d) to 
improve liver histology in non-diabetic adults with biopsy 
proven NASH (Strength: 1, Quality: B), and it is not 
recommended in NASH patients with T2DM (Strength: 
1, Quality: C)[26]. Histological improvement in NASH in 
this context should be interpreted for all lesions, except 
for improvement in fibrosis, and vitamin E is not recom-
mended for the treatment of  NAFLD-cirrhosis or cryp-
togenic cirrhosis[26,95].
Ursodeoxycholic acid-nor-ursodeoxycholic acid
The AASLD does not recommend ursodeoxycholic acid 
(UDCA) A for the treatment of  NAFLD and NASH 
(Strength 1, Quality: B), and long term, high dose 
UDCA increased the rate of  serious adverse events (the 
development of  cirrhosis, varices, cholangiocarcinoma, 
liver transplantation or death) in patients with primary 
sclerosing cholangitis[26,101]. The pharmacological proper-
ties of  norUrsodeoxycholic acid (nor-UDCA) might be 
more attractive and might later be studied in patients 
with NASH[102].
Farnesoid X receptor agonists
The bile acids secreted upon feeding undergo enterohe-
patic circulation and serve as endogenous ligands to a 
class of  nuclear hormone receptors that function as li-
gand-activated transcription factors. Farnesoid X receptor 
(FXR) belongs to this class and serves as a receptor for 
hydrophobic bile acids. In T2DM, the bile acid composi-
tion is altered. The bile acid taurochenodeoxycholic acid 
increases insulin release via the FXR dependent inhibition 
of  the KATP channels, and FXR has been described to 
improve insulin sensitivity and glucose uptake in adipose 
tissue, liver and skeletal muscle by regulating the genes 
that are important in metabolic control[103,104]. The FXR 
agonist WAY-362450 was able to decrease inflammation 
and fibrosis in a murine model of  NASH[105]. The follow-
ing results of  a 6-wk double-blind, randomised, placebo-
controlled clinical phase Ⅱ trial of  a semi-synthetic 
bile acid derivative, obeticholic acid (OCA), in patients 
with T2DM and presumed NAFLD has recently been 
published: administration of  25 or 50 mg of  OCA for 
six weeks increased insulin sensitivity and reduced the 
markers of  liver inflammation and fibrosis. A longer trial 
is ongoing with OCA in biopsy-proven NASH patients 
(Clinical trials identifier: NCT01265498)[106].
Despite the primary enthusiasm regarding the FXR 
agonists, the controversy might not be ignored due to the 
recent finding that under high fat diet conditions, FXR 
knockout (FXR-KO) mice benefited from the receptor 
deficiency, and FXR-KO protected against the HFD-
induced impairment of  fasting plasma glucose levels and 
glucose tolerance[107]. In parallel with the clinical trials, a 
better understanding of  bile acid enterohepatic circula-
tion and more research on the FXR-dependent and inde-
pendent signaling pathways are warranted.
Pre and probiotics
The intestinal microbiome has an increasing role in the 
understanding of  T2DM pathology. In a recent study, 20 
patients with histology-proven NASH were randomised 
to receive probiotics or usual care for six months. The 
probiotic treatment decreased the ASAT, and the de-
crease in IHCL was confirmed using 1H-MRS[108]. Other 
studies have suggested a potential role for prebiotic fibres 
(non-digestible carbohydrates modulating the human mi-
crobiome) in NAFLD treatment, and larger RCTs might 
provide conclusive evidence[109].
Omega 3 polyunsaturated FA
Di Minno et al[110] recently summarised the potential of  
omega-3 fatty acids for the treatment of  NAFLD re-
ported in seven human trials, the largest of  which was a 
6-mo follow-up RCT of  144 patients with NAFLD; how-
ever, the authors concluded that well-designed RCTs of  
adequate size and duration, with histological endpoints, 
are needed to assess the long-term safety and efficacy of  
such treatment.
Others
The phase 1 study to evaluate GR-MD-02, a Galectin-3 
inhibitor in patients with NASH and advanced fibrosis 
(NCT01899859) could on one day be an excellent exam-
ple of  how a long term molecular research[139,140], may po-
tentially pay out in benefiting certain patients. Galectin-3 
protein (binding to terminal galactose residues in glyco-
proteins) is implicated in the pathogenesis of  liver fibro-
sis and the results with compounds inhibiting the protein 
suggest a potential role of  these drugs in human liver 
fibrosis and even in cirrhosis in the NAFLD spectrum 
as well (Table 2). Hypothetical approaches, including the 
development of  a peripheral cannabinoid 1 receptor ago-
nist without psychiatric side effects or the supplementa-
tion of  vitamin D3 to overcome vitamin D3 deficiency 
that is highly prevalent in NAFLD[92,111,112], might have 
an effect on future therapies; however, they have yet to 
be tested and even limited evidence from concept stud-
ies is missing. There are ongoing randomised, controlled 
studies with potentially promising compounds such as 
resveratrol (500 mg three times daily for six months vs 
placebo-NCT01464801) in obese patients with NAFLD/
NASH; however, conclusions from these studies would 
be premature.
Surgical interventions
Surgical interventions including Roux-en-Y gastric bypass 
might have beneficial effects on NAFLD from calorie 
intake reduction that could increase hepatic insulin sensi-
tivity and augment postprandial GLP-1 secretion with a 
subsequently improved β cell function[26,113].
9081 July 21, 2014|Volume 20|Issue 27|WJG|www.wjgnet.com
Firneisz G. NAFLD and T2DM: The liver disease of our age?
9082 July 21, 2014|Volume 20|Issue 27|WJG|www.wjgnet.com
Ta
bl
e 
3
  
Si
ng
le
 n
uc
le
ot
id
e 
po
ly
m
or
ph
is
m
s 
as
so
ci
at
ed
 w
it
h 
no
n-
al
co
ho
lic
 f
at
ty
 li
ve
r 
di
se
as
e 
in
 g
en
om
e 
w
id
e 
as
so
ci
at
io
n 
st
ud
ie
s
R
eg
io
n
SN
Ps
R
ep
or
te
d 
ge
ne
(s
)
M
ap
pe
d 
ge
ne
O
R
R
is
k 
al
le
le
 
fr
eq
ue
nc
y 
in
 
co
nt
ro
ls
P
 v
al
ue
G
en
e 
pr
od
uc
t 
fu
nc
ti
on
 
C
on
te
xt
In
it
ia
l s
am
pl
e 
si
ze
R
ep
lic
at
io
n 
sa
m
pl
e 
si
ze
Pl
at
fo
rm
 
(S
N
Ps
 
pa
ss
in
g 
Q
C
)
R
ef
.
22
q1
3.
3  
rs
73
84
09
 
(I1
48
M
), 
rs
28
96
01
9-
G
PN
PL
A
3
PN
PL
A
3
2.
02
0.
45
0
2 
× 
10
-2
0
A
di
po
nu
tr
in
 (P
N
PL
A
3)
–n
ut
ri
tio
na
lly
 re
gu
la
te
d 
ly
so
ph
os
ph
at
id
ic
 a
cy
ltr
an
sf
er
as
e:
 e
xp
re
ss
ed
 in
 
liv
er
 a
nd
 a
di
po
se
 ti
ss
ue
. H
ig
h 
C
H
 d
ie
t i
nc
re
as
es
 
ex
pr
es
si
on
. H
as
 T
A
G
 h
yd
ro
la
se
 a
nd
 D
G
 
tr
an
sa
cy
la
se
 a
ct
iv
ity
. S
tr
on
g 
pr
ed
ic
to
r o
f s
te
at
os
is
, 
in
fl
am
m
at
io
n
 a
n
d
 fi
br
os
is
. D
ys
fu
n
ct
io
n
al
 P
N
P
L
A
3 
pr
om
ot
es
 a
cc
um
ul
at
io
n 
of
 li
po
to
xi
c 
su
bs
tr
at
es
. 
I1
48
M
–a
ss
oc
ia
tio
n 
w
ith
 H
C
C
 in
 s
ev
er
el
y 
ob
es
e 
in
di
vi
du
al
s
In
tr
on
39
2 
Ja
pa
ne
se
 c
as
es
, 
93
4 
Ja
pa
ne
se
 
co
nt
ro
ls
17
2 
Ja
pa
ne
se
 
ca
se
s,
 1
01
2 
Ja
pa
ne
se
 
co
nt
ro
l
Ill
um
in
a
[2
61
54
0]
[1
19
,1
20
]
rs
73
84
91
, 
rs
37
61
47
2,
 
rs
21
43
57
1
SA
M
M
50
SA
M
M
50
rs
60
06
47
3,
 
rs
57
64
45
5,
 
rs
60
06
61
1
PA
RV
B
PA
RV
B
1p
35
rs
66
91
84
7-
C
PT
PR
U
PT
PR
U
 - 
M
A
TN
1
1.
32
0.
77
0
7 
× 
10
-6
M
em
be
r o
f t
he
 p
ro
te
in
 ty
ro
si
ne
 p
ho
sp
ha
ta
se
 (P
TP
) 
fa
m
ily
. P
TP
s 
ar
e 
si
gn
al
in
g 
m
ol
ec
ul
es
 th
at
 re
gu
la
te
 
ce
ll 
gr
ow
th
, d
iff
er
en
tia
tio
n,
 m
ito
tic
 c
yc
le
, a
nd
 
on
co
ge
ni
c 
tr
an
sf
or
m
at
io
n
4q
13
.3
rs
22
20
54
-C
G
C
LD
H
A
L6
EP
 
- G
C
2.
54
0.
30
1
1 
× 
10
-6
 
A
lb
um
in
 g
en
e 
fa
m
ily
. M
ul
tif
un
ct
io
na
l p
ro
te
in
 
fo
u
n
d
 in
 p
la
sm
a,
 a
sc
it
ic
 fl
u
id
, c
er
eb
ro
sp
in
al
 fl
u
id
 
an
d 
on
 th
e 
su
rf
ac
e 
of
 m
an
y 
ce
ll 
ty
pe
s.
 It
 b
in
ds
 
to
 v
ita
m
in
 D
 a
nd
 it
s 
pl
as
m
a 
m
et
ab
ol
ite
s 
an
d 
tr
an
sp
or
ts
 th
em
 to
 ta
rg
et
 ti
ss
ue
s
12
6 
Eu
ro
pe
an
 
ad
ol
es
ce
nt
 c
as
es
 
- 8
02
 E
ur
op
ea
n 
ad
ol
es
ce
nt
 c
on
tr
ol
s
N
R
  I
llu
m
in
a
[2
07
88
05
] 
(im
pu
te
d)
[1
42
]
16
q2
3 
rs
11
86
41
46
-A
SL
C3
8,
 A
8
 S
LC
38
A
8
3.
14
0.
10
0
 2
 ×
 1
0-
6
A
m
in
o 
ac
id
 tr
an
sp
or
t: 
Pu
ta
tiv
e 
so
di
um
-c
ou
pl
ed
 
ne
ut
ra
l a
m
in
o 
ac
id
 tr
an
sp
or
te
r 8
In
tr
on
13
q1
4.
1
rs
73
24
84
5-
A
LC
P1
LC
P1
3.
29
0.
09
6
3 
× 
10
-6
L-
pl
as
tin
, a
n 
ac
tin
 b
in
di
ng
 p
ro
te
in
 e
xp
re
ss
ed
 in
 
he
m
op
oe
tic
 c
el
l l
in
ea
ge
s.
 It
 is
 e
xp
re
ss
ed
 b
y 
m
an
y 
so
lid
 tu
m
or
 ty
pe
s 
of
 n
on
-h
em
op
oe
tic
 o
ri
gi
n,
 
su
gg
es
tin
g 
its
 ro
le
 in
 tu
m
or
ig
en
es
is
In
tr
on
1p
21
rs
12
74
38
24
-C
LP
PR
4
LP
PR
4 
- 
PA
LM
D
2.
30
0.
44
1
5 
×
 1
0-
6
LP
PR
4:
 a
 li
pi
d 
ph
os
ph
at
e 
ph
os
ph
at
as
e,
 c
at
al
yz
es
 
th
e 
de
ph
os
ph
or
yl
at
io
n 
of
 a
 n
um
be
r o
f b
io
ac
tiv
e 
lip
id
 m
ed
ia
to
rs
, f
ou
nd
 to
 b
e 
im
po
rt
an
t f
or
 
ax
on
al
 o
ut
gr
ow
th
; P
A
LM
D
: c
yt
os
ol
ic
 is
of
or
m
 
of
 p
ar
al
em
m
in
-1
, a
 li
pi
d 
ra
ft-
as
so
ci
at
ed
 p
ro
te
in
 
im
pl
ic
at
ed
 in
 c
el
l s
ha
pe
 c
on
tr
ol
 
N
R
PA
LM
D
 g
en
e 
pr
od
uc
t -
 
[1
43
]
7p
14
rs
34
30
64
-A
In
te
rg
en
ic
TB
X
20
-
H
ER
PU
D
2
1.
31
0.
40
0
3 
× 
10
-8
TB
X2
0:
 tr
an
sc
ri
pt
io
n 
fa
ct
or
; H
ER
PU
D
2:
 n
ot
 
re
po
rt
ed
23
6 
no
n-
H
is
pa
ni
c 
C
au
ca
si
an
 w
om
en
N
R
Ill
um
in
a 
[3
24
62
3]
SN
Ps
 o
f o
th
er
 g
en
es
 
w
er
e 
al
so
 a
ss
oc
ia
te
d 
w
ith
 
qu
la
tit
at
iv
e 
tr
ai
ts
 (e
.g
. 
N
A
FL
D
 a
ct
iv
ity
 s
co
re
 
an
d
 F
D
FT
1 
- 
rs
26
45
42
4)
 
as
 d
is
cu
ss
ed
 in
 th
e 
te
xt
 
[1
23
]
2q
31
rs
15
29
09
3-
A
In
te
rg
en
ic
RP
L2
9P
8 
- 
KR
T8
P4
0
4.
13
0.
41
0
2 
× 
10
-6
RP
L2
9P
8,
 K
RT
8P
40
: p
se
ud
og
en
es
N
R
Ill
um
in
a 
[3
24
62
3]
4p
15
.2
rs
95
99
03
-A
23
23
1
SE
L1
L3
3.
81
0.
29
0
7 
× 
10
-6
 
In
tr
on
N
R
Ill
um
in
a 
[3
24
62
3]
N
ot
 a
ll 
G
W
A
S 
st
ud
ie
s 
w
er
e 
re
pl
ic
at
ed
. R
is
k 
ge
ne
 v
ar
ia
nt
s 
w
ith
 O
R 
hi
gh
er
 th
an
 1
.3
1 
ar
e 
in
di
ca
te
d 
in
 th
e 
ta
bl
e.
 B
as
ed
 o
n 
th
e 
N
at
io
na
l H
um
an
 G
en
om
e 
Re
se
ar
ch
. S
N
Ps
: S
in
gl
e 
nu
cl
eo
tid
e 
po
ly
m
or
ph
is
m
s;
 N
R:
 N
ot
 re
po
rt
ed
.
Firneisz G. NAFLD and T2DM: The liver disease of our age?
gENETICS
Familial clustering and prevalence differences according 
to ethnic origin
Although screening of  family members is not recom-
mended in NAFLD[26] based on a retrospective review of  
90 cases, the authors concluded that familial clustering is 
common, and 18% of  NASH patients had a first degree 
relative with a similar phenotype[114]. Schwimmer et al[115] 
found that NAFLD was more common in siblings (59%) 
and parents (78%), using 1H-MRS based diagnostics of  
children with biopsy proven NAFLD in a familial ag-
gregation study. After adjustment for age, sex, race and 
BMI, the study concluded that familial factors are a major 
determinant in NAFLD. Gene-environment interactions 
might have a role in the data e.g. the condition that fam-
ily members are living in a common household might 
indicate common environmental risk factors (type of  oil 
used in the diet etc.). The role of  genetic risk factors is 
supported by the differences based on ethnic origin that 
were observed in the NAFLD prevalence in multi-ethnic 
cohorts (see the Prevalence chapter and Table 1), with a 
higher prevalence in Hispanics and a lower prevalence in 
African Americans compared to non-Hispanic whites[4,16].
Genome wide association studies
Five genome wide association scans (GWAS) are report-
ed for NAFLD in the GWAS catalogue. Although these 
studies did not include case numbers that are typically 
employed in other GWA studies including T2DM, they 
provide remarkable evidence for genetic factors predis-
posing to or protecting from NAFLD. The risk polymor-
phisms with the highest ORs are summarised in Table 3, 
from the aspect of  the NAFLD binary outcomes. Dis-
cussion of  all the candidate genes is beyond the scope of  
this review.
pATATIN-lIkE pHOSpHOlIpASE 
dOmAIN CONTAININg 3 gENE (pNplA3-
AdIpONUTRIN) IN NAfld SpECTRUm 
dISEASES -bINARY TRAITS
We should outline the single nucleotide polymorphism 
in the patatin-like phospholipase domain containing a 
3-gene (PNPLA3) that is the most studied genetic risk 
variant in NAFLD. Adiponutrin is a nutritionally regulat-
ed lysophosphatidic-acyltransferase possessing the TAG 
hydrolase and DG transacylase activity. This gene is 
expressed in liver and adipose tissues, and a high carbo-
hydrate diet increases the gene expression at the mRNA 
level in the liver. Dysfunctional PNPLA3 promotes the 
accumulation of  lipotoxic substrates[116,117]. After the 
description that in carriers of  the rs738409 C/G poly-
morphism of  the PNPLA3 the hepatic lipid content was 
more than two-fold higher, PNPLA3 was subsequently 
confirmed in a Japanese GWAS as an NAFLD binary 
trait candidate gene[118,119] (Table 3). Polymorphisms in 
the SAMM50 and PARVB genes were associated with 
the development and progression of  NAFLD in this 
Japanese GWA study[119].
The quality trait data demonstrate the following find-
ings: PNPLA3 I148M (rs738409) is a genetic marker of  
progressive liver disease that is characterised with steato-
sis, inflammation and fibrosis; carriers are more insulin 
resistant and more susceptible to T2DM[120,121]; and, in a 
15-year-follow-up, there is an association of  this genetic 
variant and hepatocellular carcinoma incidence in se-
verely obese individuals, with a hazard ratio of  HCC of  
5.9x for each PNPLA3 148M allele carried (reaching the 
HR- 16x in the PNPLA3 148M homozygotes even after 
adjustment for age, gender, BMI, type 2 diabetes status 
and ALAT)[121,122].
OTHER CANdIdATE gENES (SqUAlENE 
SYNTHASE ANd COllAgEN XIII A1)-
qUAlITATIVE TRAITS
In the cases in which additional candidate genes were 
identified, qualitative traits were also assessed in GWAS. 
The NAFLD activity score was associated with the 
rs2645424 polymorphism of  farnesyl diphosphate farne-
syl transferase 1 (FDFT1), the degree of  fibrosis was as-
sociated with the rs343062 SNP, and the lobular inflam-
mation was associated with the rs1227756 polymorphism 
of  the Collagen 13 A1 gene[123].
FDFT1 is a membrane-associated enzyme located at 
a branch point in the mevalonate pathway. The encoded 
protein is the first specific enzyme in cholesterol biosyn-
thesis, catalysing the dimerisation of  two molecules of  
farnesyl diphosphate in a two-step reaction to form squa-
lene. In addition to the linkage of  FDFT1 to the NAFLD 
activity score, a coding variant in the FDFT1 gene influ-
ences the plasma cholesterol levels, likely via alteration of  
the intracellular production of  cholesterol[123,124].
Collagen XIII is one of  the nonfibrillar collagens and 
belongs to the transmembrane collagens, and a number 
of  alternatively spliced transcript variants have been de-
scribed; integrins mediate the cell adhesion to the type 
XIII collagen[125]. There is no validation of  these associa-
tions in larger studies.
In summary, we may conclude that genetic and molec-
ular research might lead to the identification of  additional 
risk and protective gene variants and this together with 
deeper understanding of  gene-environment interactions 
might provide better insight into the molecular pathology 
and identification of  molecular targets in NAFLD, which 
is the most common chronic liver disease affecting up to 
one-third of  the adult population in industrialised coun-
tries. In addition, little is known regarding the long-term 
effect of  the increasing NAFLD prevalence in paediatric 
populations.
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